BACKGROUND: Severe burn injuries are known to initiate a profound systemic inflammatory response (SIRS) that may lead to burn shock and other SIRS-related complications. Damage-associated molecular patterns (DAMPs) are important early signaling molecules that initiate SIRS after burn injury. Previous work in a rodent model has shown that application of a topical immune modulator (p38MAPK inhibitor) applied directly to the burn wound decreases cytokine expression, reduces pulmonary inflammation and edema. Our group has demonstrated that tranexamic acid (TXA)-in addition to its use as an antifibrinolytic-has cell protective in vitro effects. We hypothesized that administration of TXA after burn injury would attenuate DAMP release and reduce lung inflammation.
D espite significant improvements in burn care over the past 60 years, severe burns that are refractory to current fluid resuscitation practices continue to challenge burn care providers, and remain a common cause of burn-related mortality and morbidity. This is primarily because of inflammatory and infectious complications resulting from inhalation injury and/or an overstimulated and dysfunctional immune response. 1 The loss of microvascular integrity is central to burn pathophysiology and leads to large fluid volume resuscitation requirements, ultimately precipitating widespread tissue edema and end organ dysfunction. 2 The vascular endothelial tight junctions and glycocalyx brush border have been studied in trauma and are postulated to contribute to as much as 70% of vascular luminal integrity. 3 Furthermore, traumatic injury is known to significantly alter glycocalyx structure and endothelial cell tight junctions through systemic inflammatory cell signaling, resulting in hyperpermeability, increased capillary leak, tissue edema and organ failure. 3, 4 Preclinical data have demonstrated that endovascular integrity is preserved with plasma-based resuscitations when compared to crystalloid in hemorrhagic shock models. 4, 5 In large clinical trials, plasma-based resuscitation has been shown to decrease vascular permeability after hemorrhage resulting from injury, resulting in improved outcomes. 6 The preponderant evidence clearly demonstrates that blood product resuscitation is superior to crystalloid-and colloid-based resuscitations. This phenomenon, however, has not been studied to any extent in burn injury. Despite the well-documented inferiority of crystalloid and colloid fluid solutions in trauma, they remain the mainstay of fluid resuscitation in the setting of burn injury. Given the deleterious effects on endovascular integrity caused by salt-based fluid resuscitation, adjuncts that may reduce these negative effects are desirable.
Recent literature has shown that early systemic inflammatory signaling after injury is induced by a large group of circulating molecules collectively referred to as damage-associated molecular patterns (DAMPs) and is responsible for the initial propagation of systemic inflammatory response (SIRS) and the endotheliopathy of trauma. 7, 8 Previous work in a rodent model has shown that application of a topical inhibitor of p38 MAPK applied directly to the burn wound decreases systemic cytokine expression and reduces pulmonary inflammation and edema. 9 Recent evidence also demonstrates that tranexamic acid (TXA)-in addition to its use as an antifibrinolytic-has anti-inflammatory effects in vivo. 10 Furthermore, our group has characterized important links between DAMPs and endothelial cell tight junctions as well as leukocyte inflammatory signaling. The results of our preliminary work-which are in agreement with recently published results by Diebel et al.
11
-show that TXA preserved tight junction integrity and protected endothelial monolayer in vitro (unpublished). Therefore, we hypothesized that administration of TXA after burn injury would attenuate DAMP release and reduce lung inflammation in a rodent burn model. As the anti-inflammatory effects of TXA and the topical p38 MAPK inhibitor are well established, we focused our investigation on elucidating their effects on early (prior to cytokine release from inflammatory cells) damage molecule release.
9,12 Specifically, we studied the effects of TXA on the plasma levels of mtDNA and lung inflammation after severe burn and compared them with the effects of a topical p38 MAPK inhibitor.
METHODS

Experimental Animals
All experiments were performed in accordance with the guidelines set forth by the National Institutes of Health.
Institutes of Health for care and use of animals. Approval for the experimental protocol was obtained from the Maine Medical Center Research Institute's Institutional Animal Care and Use Committee. Age-and weight-matched male C57/BL6 mice (Charles-River Laboratories) weighing 22 g to 25 g were allowed to acclimate for 1 week before being used in any experiment. Animals had unrestricted access to standard chow and water ad libitum throughout the course of the study. Using STATA 8.0 and assuming a power of 0.9 and alpha of 0.05, we determined that 12 animals per group would be required for these experiments.
Burn Procedure
C57/BL6 male mice were anesthetized via intraperitoneal (IP) injection of a ketamine/xylazine mixture. The dorsal hairs were clipped, and animals were placed in an insulating mold device with an opening calculated to expose 40% total body surface area. After immersion in 80°C water for 30 seconds (to insure a full thickness injury), the burn area was scrub debrided with dry sterile gauze (Fig. 1 ). Animals were resuscitated by IP injection with lactated Ringer's solution according to the following formula: 4 mL Â (%TBSA burn) Â weight (kg). Each animal received 0.3 mg/kg buprenorphine (Buprenex; Reckitt & Coleman Pharmaceuticals) at 1-hour postinjury by subcutaneous injection. Animals were housed by experimental group with no more than five per cage. Sham animals were subjected to identical procedure, resuscitation, and buprenorphine injection, but immersed in room temperature water.
Our previous study (9) has shown that topical p38 MAPK inhibitor (SB 202190) attenuated burn-induced SIRS in mice. DAMP release is postulated to be the earliest event in the immune response to injury. 7 Thus, we verified whether p38 MAPK inhibition could also suppress burn-induced systemic release of DAMPs. For topical inhibition of p38 MAPK, the inhibitor used was 1 Â 10 −3 M SB202190 (Tocris, Minneapolis, MN). Topical inhibitor was applied directly to the burn wound in 2% solution of hypromellose (Sigma, St. Louis, MO) in phosphate buffered saline (PBS). Dose-response studies were performed in a previous topical inhibitor study. 9 Previous research has established that TXA has antiinflammatory effects similar to p38 MAPK inhibitor including suppression of pro-inflammatory cytokines. 12 For TXA treatment, mice received IP injection of a 25-mg/mL solution of TXA (Mylan, Rockford, IL) in PBS to a final dose of 100 mg per kg body weight. PBS was used as the sham treatment vehicle for topical treatments. Each experimental group consisted of four to five animals.
Plasma Preparation
Mice were sacrificed by isoflurane inhalation to effect. Blood was obtained through heart puncture and transferred to Eppendorf tubes containing 100 μL of 3.8% sodium citrate. Platelet-free plasma was prepared by two cycles of centrifugation each at 2,000g for 10 minutes.
Determination of Mitochondrial DNA Content in Plasma
mtDNA was isolated from plasma using a Qiamp DNA Blood Mini Kit (51106). Manufacturer's instructions were followed using 150 μL of PBS added to 50 μL of plasma sample. Fifty microliters of mtDNA was eluded from the columns. Plasma levels of mtDNA were determined using quantitative PCR. Five microliters of the isolated plasmid DNA was analyzed using Biorad iQ Sybr Green Supermix and primers: sense (5′-CCCAGCTACTACCATCATTCAAGT) as (5′-GATGGTTTGGGAGATTGGTTGATGT) and cycled 40 times on a Biorad CFX real-time machine. Absolute numbers were calculated from isolated mouse mtDNA internal standard curve.
Determination of Syndecan 1 Content in Plasma
Plasma samples of 40 μL to 50 μL were analyzed according to manufacturer's instructions by Mouse Syndecan-1/SDC1 Picokine ELISA Kit (Boster, Pleasanton, CA) or Murine CD138 ELISA Set (MyBioSource, San Diego, CA). 
Study of Macrophage Content in Lungs
Mouse lungs were fixed overnight in 10% neutral formalin, then transferred for 24 hours to 70% ethanol and after that passed to the Histopathology core of MMCRI for histochemical staining. In brief, paraffin sections were immunoperoxidase stained for macrophages using the rabbit anti-Mac1 antibodies (Abcam, Cambridge, MA) and counterstained with hematoxylin. Photographs of five random sections of lungs per each animal were taken using 40Â objective. Image J program was used to analyze the abundance of macrophages in lung sections (excluding cell-free areas, such as alveoli) that was expressed as mean macrophage number per standard square unit.
Statistical Analysis
The experiments were triplicated with consistent results, and the results of representative experiments are shown. Quantitative data were analyzed, and graphs were produced using the GraphPad Prism program. Mean values of analyzed parameters and standard deviations (SD) are presented in the graphs. Of three standard experimental groups, we always performed two comparisons: burn to control and burn + treatment to burn. To adjust for these two comparisons, a Bonferroni adjustment was performed where p values were required to be less than 0.05/2 or 0.025. Only p values less than 0.025 are reported as significant. When an additional treatment group was added, the third comparison, between two burned groups with different treatment types (TXA and TXA + p38 MAPK inhibitor) was made, and the required p value was adjusted to 0.05/3 or 0.017. We used the unpaired t test to determine the significance of differences between compared values. When values exhibited unequal variances, we applied the unpaired t test with Welch correction.
RESULTS
Topical Application of a p38 MAPK Inhibitor Suppresses the Release of Circulating mtDNA in Mice After Severe Burn
We used circulating mitochondrial DNA (mtDNA) as a surrogate for generalized systemic DAMP release. The topical application of the p38 MAPK inhibitor resulted in a statistically significant reduction in plasma mtDNA levels (Fig. 2) .
TXA Suppresses the Release of Circulating mtDNA in Mice After Severe Burn
Tranexamic acid demonstrated a statistically significant reduction in plasma mtDNA levels (Fig. 3) . The suppression was similar when topical p38 MAPK inhibitor was applied simultaneously with TXA (Fig. 3) , and no further decrease of mtDNA plasma levels was observed.
TXA and Topical p38 MAPK Inhibitor Suppress Macrophage Infiltration in Mouse Lungs
Topical p38 MAPK inhibitor significantly reduced lung inflammation as represented by decreased macrophage infiltration (Fig. 4) . Representative images further support these findings. Tranexamic acid significantly reduced lung inflammation as represented by decreased macrophage infiltration (Fig. 5) . Representative images further support these findings. Combined treatment of burned mice with TXA and p38 MAPK inhibitor did not show any further decrease of macrophage infiltration (Fig. 5) .
TXA Alone or in Combination With p38 MAPK Inhibitor Does Not Suppress the Shedding of Syndecan-1 Induced by Severe Burns Tranexamic acid did not suppress the shedding of syndecan-1 from endothelial cells (Fig. 6 ). Combined treatment of mice with TXA and topical p38 MAPK inhibitor similarly demonstrated no decrease in circulating syndecan levels (Fig. 6) .
DISCUSSION
Fluid resuscitation of the critically injured burn patient can be particularly challenging for burn care providers. Adjunct treatments that could decrease fluid volume requirements may lead to reduced morbidity and mortality in this trauma population. Whereas plasma resuscitation is often used as a "rescue" treatment in burns, its widespread use is neither practical nor without risk. 13 Crystalloid and colloid (usually albumin) fluid resuscitation remain the standard in burns despite the growing body of evidence of its deleterious effects on glycocalyx integrity in trauma.
14 Currently, no viable alternative exists. These fluids exacerbate the capillary leak and tissue edema associated with burn-induced SIRS and worsen organ dysfunction. The role of early damage molecule (DAMP) signaling in the propagation of this SIRS response is now well established in the trauma literature. 7, 8, 15 Thus, treatment strategies aimed at Figure 2 . p38 MAPK inhibitor suppresses the release of mtDNA to mouse bloodstream induced by severe burn. p38 MAPK inhibitor SB 202190 was topically applied immediately after mice underwent burning procedure. Mean and SD of mtDNA plasma content are shown. The mean of the control (sham) group was taken as a reference (100%) and used to divide each individual mean. The statistical significance of differences between sham (n = 4) and burn (n = 4), and burn and burn + p38 MAPK inhibitor (n = 7) groups was determined using t test with Welch correction.
reducing or blocking the effectiveness of these early inflammation signals are promising therapeutic options to improve outcomes from burn-induced SIRS-related complications. We have demonstrated that topical inhibition of a key inflammatory signaling regulator-p38 MAPK-can effectively reduce the levels of an important circulating mitochondrial DAMP. Similarly, we have shown that TXA decreases circulating mtDNA, though the mechanism is unclear. The recent in vivo study by Teng et al. 12 demonstrated that TXA suppresses NF-κB pathway signaling. In addition to mitochondrial DAMPs, we believe that downregulation of inflammatory nonmitochondrial DAMPs with either treatment is also likely. Our data also show that suppression of mtDNA release is associated with a reduction in lung inflammation as demonstrated by the relative extent of inflammatory cell infiltration. Because pulmonary complications are the leading cause of death after severe burns, the apparent effectiveness of these adjunct treatments is encouraging for their ability to reduce lung inflammation.
The endothelial glycocalyx is a "brush border" between the stream of circulating blood and the endothelial cell monolayer.
14 This structure lines all blood vessels throughout the body and within organs and is composed principally of glycosaminoglycans, proteoglycans, heparin sulfates, and chondroitin sulfates. The glycocalyx serves a barrier function and is essential to regulation of fluid and cellular extravasation into the interstitium. The glycocalyx accounts for most of the vascular luminal integrity of visceral capillary beds and is thus critical to mitigating tissue edema.
14 Syndecans are a unique endothelial cell transmembrane bound protein, considered the "root and stem" of the glycocalyx structure. After injury, these transmembrane proteins are cleaved and shed as a result of leukocyte-mediated enzymatic breakdown-compromising the structure of the barrier that leads to capillary leak.
14 Syndecan-1 is frequently used as a circulating marker of glycocalyx shedding. Our results showed no significant difference in the quantity of syndecan-1 released into the circulation (Fig. 6 ) between the untreated burn animals and either treatment group. In fact, syndecan-1 levels trended slightly higher in both treatment groups when compared to the burn. Our hypothesis regarding syndecan-1 shedding was not supported by these experiments. This finding would seem to contradict the reduction in early inflammatory DAMP release and notable decrease in lung inflammation. This may simply mean that shedding of syndecan-1 is a gross marker of systemic inflammation and endothelial injury. Interestingly, Deibel et al. 11 has demonstrated that TXA reduces syndecan-1 shedding in an in vitro microfluidics model using Human Umbilical Vein Endothelial Cells (HUVEC)s. While their findings contradict our study, we feel the in vivo nature of our work is a more complex biochemical interaction than the in vitro model. Furthermore, our time point of sacrifice at 5 hours may not have captured differences in earlier glycocalyx shedding events as was evaluated in the Diebel et al. study. While one would anticipate the treatment groups to have lower circulating syndecan-1 levels, we think this finding can be potentially explained in a few ways. First, animals were sacrificed at 5 hours after injury and thus differences may not have had enough postinjury time to develop. Similarly, distinguishing events may occur much earlier on the order of 1 hours to 2 hours after injury. Second, shedding of syndecan-1 is a factor associated with systemic inflammation in general (regardless of etiology). 16 The levels of syndecan Figure 3 . TXA suppresses the release of mtDNA to mouse bloodstream induced by severe burn. Mice received intraperitoneal injection of TXA immediately after undergoing burning procedure. A group of mice received both TXA injection and topical p38 MAPK inhibitor. Mean and SD of mtDNA plasma content are shown. The mean of the control (sham) group was taken as a reference (100%) and used to divide each individual mean. The statistical significance of differences between sham (n = 8) and burn (n = 9), burn and burn + TXA (n = 10), and burn + TXA and burn +TXA + p38 MAPK inhibitor (n = 10) groups was determined using t test with Welch correction.
in circulation do not necessarily correlate with the "brush border" integrity as new endothelial glycocalyx is reconstituted. Furthermore, glycocalyx repopulation after injury is poorly understood. 14, 17 The circulating levels therefore do not fully describe what is happening on the vessel wall. Third, other cell types can produce syndecan-1 and release it into circulation. 17 Shed syndecan-1 may also have a role as an acute phase reactant; however, this is a speculation. Nonetheless, the clear evidence of decreased DAMP release and reduced lung inflammation in the treatment groups is reassuring. Future work will focus on imaging of the glycocalyx under experimental conditions. This study has several important limitations. First, we used a brief course experimental model with analyses of DAMP release and syndecan-1 shedding in 5 hours after initial injury. This may have missed latent DAMP release events in a longer-term experiment. In addition, we did not evaluate any parameter of organ function in our experiments, although we did observe that both TXA-and p38 MAPK-treated mice demonstrated better activity during recovery when compared with untreated burned animals. Most importantly, a murine model does not fully represent human immune response; particularly as it relates to burn trauma. 9 In future experiments, we plan to use a swine burn model where we can evaluate these treatments in a clinically relevant fluid resuscitation event. Furthermore, the porcine model will allow for evaluation of organ function with more fidelity and applicability to human burn injury.
Interestingly, while TXA and the topical p38 MAPK inhibitor produced similar results, combined treatment did not show any synergistic effects. Given these findings, TXA-with its more practical clinical application-may be effective as a stand-alone agent. Since it may be administered intravenously, it can integrate seamlessly with standard acute burn care practices. TXA also has a well-established track record of use in humans Figure 4 . p38 MAPK inhibitor suppresses the burn-induced increase of macrophage presence in mouse lungs. p38 MAPK inhibitor (SB 202190) was topically applied immediately after mice underwent burning procedure. Mouse lungs were formalin fixed, paraffin sectioned, and stained for macrophage marker Mac1 (brown). The abundance of macrophages per tissue section area was calculated using Image J program. Mean and SD of macrophage abundance are shown. The mean of the control (sham) group was taken as a reference (100%) and used to divide each individual mean. The statistical significance of differences between sham (n = 3) and burn (n = 4), and burn and burn + p38 MAPK inhibitor (n = 4) groups was determined using t-test with Welch correction. Representative micrograph images are displayed. Figure 5 . TXA inhibitor suppresses the burn-induced increase of macrophage presence in mouse lungs. Mice received intraperitoneal injection of TXA immediately after undergoing burning procedure. A group of mice received both TXA injection and the topical p38 MAPK inhibitor. Mouse lungs were formalin fixed, paraffin sectioned, and stained for macrophage marker Mac1 (brown). The abundance of macrophages per tissue section area was calculated using Image J program. Mean and SD of macrophage abundance are shown. The mean of the control (sham) group was taken as a reference (100%) and used to divide each individual mean. The statistical significance of differences between sham (n = 4) and burn (n = 4), burn and burn + TXA (n = 4), and burn + TXA and burn + TXA + p38 MAPK inhibitor (n = 4) groups was determined using t-test with Welch correction. Representative micrographs are displayed.
with a well-defined and acceptable side effect profile. Furthermore, TXA may have a role in mitigating the negative effects of fluid resuscitation in other nonhemorrhagic shock conditions, such as sepsis. Preclinical research into a potential role for TXA in septic shock resuscitation is warranted, and future work is planned; however, this remains speculation.
CONCLUSION
Both TXA and topical p38 MAPK inhibitor demonstrated the potential to attenuate burn-induced DAMP release and SIRS while reducing lung inflammation. Beyond its role as an antifibrinolytic, TXA may have significant anti-inflammatory effects pertinent to burn resuscitation. Further study is required; however, TXA may be a useful adjunct treatment in burn resuscitation and other nonhemorrhagic shock conditions. AUTHORSHIP D.W.C., I.P. and J.R. were the primary contributors to the conception, design, data analysis and interpretation of results. D.W.C., I.P. and T.S. performed all animal experiments. D.K., C.K., T.S., and K.P. performed data collection and analysis. D.W.C., and I.P. drafted the article. All authors contributed to revising the article and critical review. Figure 6 . TXA alone or in combination with p38 MAPK inhibitor does not suppress the shedding of syndecan-1 induced by severe burn. Mice received intraperitoneal injection of TXA immediately after undergoing burning procedure. A group of mice received both TXA injection and topical p38 MAPK inhibitor. Plasma concentration of shed syndecan-1 was determined using ELISA. Mean and SD of syndecan-1 plasma content (ng/mL) are shown. The statistical significance of differences between sham (n = 8) and burn (n = 9), burn and burn + TXA (n = 10), and burn and burn + TXA + p38 MAPK inhibitor (n = 10) groups was determined using t test with Welch correction.
As far as TXA, I mean we -I guess we are unclear about how exactly that is acting. There has been a lot written about, you know, the various effects it has on NFkB inflammatory pathway and so we thought that that at least made the most sense.
We confirmed those results but I think you know we're still kind of trying to figure out what exactly TXA's mechanism and that's ongoing work, as well.
To Dr. Cuschieri, why did we look at both of these, initially the TXA we just kind of added to the study just to see what it would do because, again, we were sort of playing around with it as we were doing other work in hemorrhage shock in our lab and we were just kind of surprised by the finding.
But I think, thinking more globally, our thought was that we really don't have a good resuscitation adjunct for nonhemorrhagic shock and so we were thinking toward sepsis or something like that where a topical inhibitor wouldn't be effective.
And so in future work we're actually going to look at a sepsis model and see if the sepsis resuscitation can be improved or at least total volumes could be improved in that situation. So that was the reason why we kept it in.
And the reason for TXA was just we thought that, again, it kind of goes against our theory with topical inhibition as a systemically administered drug, but we thought that it's side-effect profile was pretty low and well understood as it is generally used in trauma so we thought that that was at least a tolerable violation of the rule.
